R.G.F. declares research funding from Kite (a Gilead company) and Novartis; consultancy or advisory board roles for Autolus, Kite (a Gilead company) and Sanofi; honoraria from Sanofi; and travel support from Orca Bio. F.L.L. declares research funding from 2SeventyBio, Allogene, Bristol Myers Squibb (BMS), Kite (a Gilead company), and Novartis; consultancy roles with A2 Biotherapeutics, Allogene, Amgen, Bluebird Bio, BMS, Calibr, Caribou, Celgene, Cellular Biomedicine Group, Cowen, EcoR1 Capital, Emerging Therapy Solutions, Gerson Lehrman Group, GammaDelta Therapeutics, Gilead Company, Iovance, Janssen, Kite (a Gilead company), Legend Biotech, Novartis, Pfizer, Sana, Umoja, Wugen; honoraria from the American Society of Hematology, Aptitude Health, BioPharma, Clinical Care Options Oncology, Communications CARE Education, iMedX, and the Society for Immunotherapy of Cancer; travel support from American Society of Hematology and Kite (a Gilead company); and patents and royalties for cellular immunotherapy from the Moffit Cancer Center.